While we wait on CD12 results, an update on the long-hauler trial, BLA submissions for HIV, the Philippines, etc. I’ve tried to keep busy educating myself by reading medical research articles of which I must admit, have absolutely no training. At all.

Nevertheless, I was intrigued by the PatentScope document (WO2021026028 METHODS FOR TREATING OR PREVENTING CANCERS INVOLVING THE ADMINISTRATION OF ANTI-CCR5 RECEPTOR AGENTS (wipo.int) and impact leronlimab has on angiogenesis. I had no idea.

“Tumor neoangiogenesis is required for tumor growth and metastasis, the effect of leronlimab on angiogenesis was assessed. It was found that leronlimab interfers with tumor angiogenesis, which suggests a mechanism for the reduction of metastatic burden observed.”

I also read in the following article that has likely already been shared here that blocking CCR5 impairs angiogenesis and helps mediate VEGF.
CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment | Carcinogenesis | Oxford Academic (oup.com)

This got me thinking about another possible opportunity of leronlimab for macular degeneration (wet form). Many of the drugs currently used are re-purposed cancer treatments that target VEGF. Currently, this is about a $10B market with a projected CAGR of over 6%.

So, I am asking the scientists on the board to evaluate whether leronlimab could possibly be an effective treatment for AMD.

Saving lives, Saving vision?

Thanks!